Loading...

PBYI PUMA BIOTECHNOLOGY INC Management Changes 8-K Filing

PM B

PBY

PUMA BIOTECHNOLOGY INC

(PBYI)

2025 8-K

Show Summary

Show Summary

Financial Statements

Financial Results

Q3 Financial Results

Patent Infringement Case

Patent Infringement Case

Lawsuit against AstraZeneca...

Earnings Report

Annual Meeting Approval

Lawsuit against AstraZeneca...

Earnings Reports

Lawsuit against AstraZeneca

Earnings Report

Presentation at Oncology Co...

Earnings Reports

Acceptance of Trial at Conf...

Bylaws Amendment

Earnings Report

Annual Meeting of Stockholders

Earnings Report

Earnings Report

Regulation FD Disclosure

External Links:

On May 8, 2025, Puma Biotechnology, Inc. terminated Jeff J. Ludwig from his role as Chief Commercial Officer, with a possibility of severance upon signing a release agreement. The company will not appoint a new CCO, instead redistributing his duties

AI Assistant

PUMA BIOTECHNOLOGY INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.